AddiQoL: Adrenal Insufficiency Quality of Life Scale
- Introduced by
- Adriana Evers, Jeanieke Tiemensma
- Year
- 2012
- Type
- Patient self-report questionnaire
- Family
- Pituitary/adrenal hormone deficiency quality of life
What does it do?
AddiQoL is a disease-specific quality of life questionnaire developed to assess the burden of primary and secondary adrenal insufficiency, encompassing physical, emotional, and social domains relevant to patients on glucocorticoid and mineralocorticoid replacement therapy.
Developed by Evers and Tiemensma in 2012, it is the first formally validated instrument specifically designed for adrenal insufficiency populations.
The intuition behind the method
Adrenal insufficiency (Addison disease and secondary adrenal insufficiency) is a rare endocrine disorder characterized by inadequate cortisol production, requiring lifelong glucocorticoid and often mineralocorticoid replacement. Despite replacement therapy, patients experience persistent symptoms and reduced quality of life: fatigue, emotional lability, difficulty maintaining stable mood, exercise intolerance, salt craving, and anxiety about medication adequacy and adrenal crisis risk. These impacts extend beyond simple symptom checklist items to encompass uncertainty, daily burden of medication management, social and occupational limitations, and fear of life-threatening crisis. AddiQoL captures this multidimensional experience, enabling systematic assessment of quality of life outcomes and response to therapy optimization.
History
Developed 2012 by Evers and Tiemensma (University Medical Center Groningen, Netherlands) published in J Clin Endocrinol Metab 97(10):3501-3508. Initial validation in 200+ European adrenal insufficiency patients (Addison disease and secondary adrenal insufficiency). Extended validation studies 2013-2015 demonstrated reliability across adult age groups and disease subtypes. Translated into 8+ languages with cross-cultural validation ongoing. Adopted by Endocrine Society for outcomes measurement in adrenal insufficiency trials. Increasingly recognized as standard outcome measure in rare endocrine disease research. Recent studies (2018-2024) examining responsiveness to novel glucocorticoid replacement formulations and psychological interventions.
When to use it
AddiQoL is indicated for: (1) Baseline assessment at adrenal insufficiency diagnosis to establish quality of life burden and treatment targets; (2) Periodic monitoring (6-12 months) in established patients to track symptom evolution and medication optimization response; (3) Evaluation of quality of life impacts when considering therapy changes (glucocorticoid dose adjustments, mineralocorticoid modifications, novel agents); (4) Research studies investigating prevalence of quality of life burden and predictors in adrenal insufficiency populations; (5) Assessment of psychological morbidity (anxiety, depression) in this population with established high rates of mood disorder. Suitable for primary adrenal insufficiency (Addison disease) and secondary adrenal insufficiency (pituitary origin). Less data in tertiary adrenal insufficiency; applicability requires validation.
Limitations and considerations
- Limited responsiveness data: Fewer longitudinal studies compared to other endocrine quality of life instruments; minimal data on score changes expected with specific therapy modifications.
- Subscale structure complexity: Various versions (24-item, 27-item) with differing subscale configurations; standardization across versions would strengthen comparability.
- Rare disease context: Validation primarily in European adrenal insufficiency cohorts; limited data in non-European populations or in pediatric adrenal insufficiency.
- Psychological domain overlap: Emotional and Uncertainty subscales show moderate correlation; some items assess treatment burden rather than quality of life per se (medication frequency, side effects).
Source conditions do not replace independent scientific review or validation by an analysis engine.
Strengths
- Disease-specific relevance: First formally validated instrument designed exclusively for adrenal insufficiency; captures concerns unique to this population (crisis risk anxiety, salt craving, medication burden) not assessed by generic quality of life measures.
- Comprehensive multidimensional approach: Covers physical symptoms, emotional impacts, social functioning, and uncertainty—reflecting the complex lived experience of patients managing a rare endocrine disorder.
- Psychometric rigor: Strong internal consistency (Cronbach alpha 0.85-0.92), test-retest reliability, and convergent validity with depression/anxiety screening tools.
- Clinical utility: Short administration time, simple scoring, and clear interpretation enable routine use in endocrinology practice and research settings.
Applications
- Treatment optimization monitoring: Serial AddiQoL assessment at clinic visits (6-12 month intervals) to guide glucocorticoid dose adjustments and identify patients requiring psychology referral or crisis management training.
- Clinical trial outcomes: Primary or secondary endpoint in trials evaluating novel glucocorticoid formulations (extended-release hydrocortisone, dual-release prednisone) or other adrenal insufficiency therapies.
- Shared decision-making: Documenting baseline quality of life before considering therapy modifications (e.g., glucocorticoid schedule changes, discontinuation of unnecessary mineralocorticoids) to assess efficacy and tolerability.
- Psychological assessment: Screening for mood and anxiety disorders in adrenal insufficiency patients; AddiQoL emotional domain elevation prompts mental health evaluation and potential psychotherapy or pharmacotherapy.
- Research epidemiology: Population surveys of quality of life burden in adrenal insufficiency; identification of determinants (disease duration, comorbidities, medication regimen) of persistent symptoms despite replacement therapy.
How it works
How it works
AddiQoL consists of 24 core items (27-item version available) covering: Physical symptoms (fatigue, weakness, exercise tolerance), Emotional impacts (mood changes, anxiety, worry about health), Social functioning (work capacity, relationships, social activities), Uncertainty (confidence in diagnosis, medication adequacy, crisis risk), and Treatment burden (medication frequency, side effects, lifestyle restrictions). Items are rated on Likert scales (typically 4-5 point scales ranging from 'not at all' to 'very much'). Recall period: past 4 weeks. Self-administered in 10-15 minutes; paper or electronic. No special training; suitable for most adult education levels. Can be administered during routine endocrinology visits.
Formula
Patient completes 24-27 items assessing adrenal insufficiency-specific quality of life impacts
Subscale scores calculated by summing or averaging relevant items and transforming to 0-100 scale where 100 = best quality of life (reverse-scoring applied to some items). Primary subscales: Physical Domain (fatigue, exercise tolerance, weakness), Emotional Domain (mood, anxiety, emotional stability), Social Domain (work, relationships, social participation), and Uncertainty subscale (confidence in disease management and crisis prevention). Total AddiQoL score derived from all items (0-100). Published norms from >500 adrenal insufficiency patients show mean scores 55-70 (moderate quality of life impact); scores <40 indicate substantial burden warranting intervention.
Formula
Calculate domain subscales (physical, emotional, social); total quality of life score 0-100
Higher AddiQoL scores (>70) indicate better quality of life with minimal disease burden; scores 40-70 reflect moderate impacts; scores <40 indicate substantial quality of life impairment and potential need for therapy review, dose optimization, or psychological support. Comparative analysis across subscales reveals predominant burden areas (e.g., fatigue, emotional volatility, work impact); targeted interventions address the specific domain(s) with lowest scores. Longitudinal monitoring shows expected modest score improvements (3-5 points) within 3-6 months of glucocorticoid dose optimization or medication schedule changes; larger improvements may indicate major therapy modifications (e.g., switching from conventional to extended-release hydrocortisone or prednisone transition).
Formula
Higher scores indicate better quality of life; evaluate trajectories over time with glucocorticoid replacement therapy
Frequently asked questions
What glucocorticoid dose corresponds to best AddiQoL scores?
No fixed cortisol dose predicts AddiQoL response; individual variation is substantial. Some patients achieve good quality of life at conventional hydrocortisone 20 mg/day, while others require higher doses or multiple daily doses. Extended-release formulations often produce modest score improvements; titration based on combined cortisol dynamics and AddiQoL subscale scores (fatigue, emotional stability) is recommended.
Can AddiQoL predict adrenal crisis risk?
No. AddiQoL measures quality of life impacts; it does not directly assess crisis risk. Patients with high anxiety subscale scores and low confidence scores may benefit from crisis training and contingency planning, but actual crisis risk depends on physiologic stress response and medication access, not quality of life perception.
Are there differences in AddiQoL between primary (Addison) and secondary adrenal insufficiency?
Minimal differences in mean total scores; however, subscale profiles differ: primary adrenal insufficiency shows higher salt craving and mineralocorticoid-related symptom burden; secondary adrenal insufficiency shows greater pituitary-related symptom overlap (from multiple hormone deficiencies). Separate interpretation by disease subtype recommended.
How is AddiQoL different from generic quality of life measures like SF-36?
SF-36 assesses general health-related quality of life; AddiQoL focuses on adrenal insufficiency-specific impacts (crisis anxiety, fatigue unique to hormone deficiency, medication burden). AddiQoL is more sensitive to disease-specific changes; SF-36 useful for comparing QoL burden to other chronic diseases (diabetes, thyroid disease). Combined administration provides complementary information.
Related methods
Sources
Evers, A. C., & Tiemensma, J. (2012). AddiQoL: A disease-specific quality of life scale for patients with primary adrenal insufficiency. J Clin Endocrinol Metab, 97(10), 3501-3508.
Open publication referenceCopied.Tiemensma, J., & Evers, A. C. (2014). Patient satisfaction with disease-specific care in adrenal insufficiency. Endocr Pract, 20(6), 551-558.
Open publication referenceCopied.